These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17570760)

  • 1. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein.
    Chen S; Yu M; Jiang T; Deng Y; Qin C; Qin E
    DNA Cell Biol; 2007 Jun; 26(6):361-7. PubMed ID: 17570760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae.
    Nguyen NL; Kim JM; Park JA; Park SM; Jang YS; Yang MS; Kim DH
    Protein Expr Purif; 2013 Apr; 88(2):235-42. PubMed ID: 23376461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.
    Mota J; Acosta M; Argotte R; Figueroa R; Méndez A; Ramos C
    Vaccine; 2005 May; 23(26):3469-76. PubMed ID: 15837370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
    Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
    J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.
    Izquierdo A; García A; Lazo L; Gil L; Marcos E; Alvarez M; Valdés I; Hermida L; Guillén G; Guzmán MG
    Arch Virol; 2014 Oct; 159(10):2597-604. PubMed ID: 24841761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
    Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
    Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.
    Chen HW; Hu HM; Wu SH; Chiang CY; Hsiao YJ; Wu CK; Hsieh CH; Chung HH; Chong P; Leng CH; Pan CH
    PLoS One; 2015; 10(12):e0145717. PubMed ID: 26714037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solution structure of the envelope protein domain III of dengue-4 virus.
    Volk DE; Lee YC; Li X; Thiviyanathan V; Gromowski GD; Li L; Lamb AR; Beasley DW; Barrett AD; Gorenstein DG
    Virology; 2007 Jul; 364(1):147-54. PubMed ID: 17395234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recombinant envelope glycoprotein domain III of dengue virus inhibit virus infection].
    Lu P; Wei Y; Cao SC; Li JD; Liu QZ; Zhang QF; Li C; Miao F; Zhang S; Hang XT; Liang MF; Li DX
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Jun; 22(3):177-9. PubMed ID: 19031695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.
    Etemad B; Batra G; Raut R; Dahiya S; Khanam S; Swaminathan S; Khanna N
    Am J Trop Med Hyg; 2008 Sep; 79(3):353-63. PubMed ID: 18784226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and biophysical analysis of sero-specific immune responses using epitope grafted Dengue ED3 mutants.
    Kulkarni MR; Islam MM; Numoto N; Elahi M; Mahib MR; Ito N; Kuroda Y
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1438-43. PubMed ID: 26160751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes.
    Khanam S; Etemad B; Khanna N; Swaminathan S
    Am J Trop Med Hyg; 2006 Feb; 74(2):266-77. PubMed ID: 16474083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge.
    Bray M; Men R; Lai CJ
    J Virol; 1996 Jun; 70(6):4162-6. PubMed ID: 8648761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.
    Zhao H; Jiang T; Zhou XZ; Deng YQ; Li XF; Chen SP; Zhu SY; Zhou X; Qin ED; Qin CF
    PLoS One; 2014; 9(1):e86573. PubMed ID: 24466156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
    Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
    Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
    Blaney JE; Matro JM; Murphy BR; Whitehead SS
    J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.